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Abstract
Introduction: When making treatment decisions, oncologists often stratify breast cancer (BC) into a low-risk group
(low-grade estrogen receptor-positive (ER+)), an intermediate-risk group (high-grade ER+) and a high-risk group
that includes Her2+ and triple-negative (TN) tumors (ER-/PR-/Her2-). None of the currently available gene signatures
correlates to this clinical classification. In this study, we aimed to develop a test that is practical for oncologists and
offers both molecular characterization of BC and improved prediction of prognosis and treatment response.
Methods: We investigated the molecular basis of such clinical practice by grouping Her2+ and TN BC together
during clustering analyses of the genome-wide gene expression profiles of our training cohort, mostly derived
from fine-needle aspiration biopsies (FNABs) of 149 consecutive evaluable BC. The analyses consistently divided
these tumors into a three-cluster pattern, similarly to clinical risk stratification groups, that was reproducible in
published microarray databases (n = 2,487) annotated with clinical outcomes. The clinicopathological parameters of
each of these three molecular groups were also similar to clinical classification.
Results: The low-risk group had good outcomes and benefited from endocrine therapy. Both the intermediate-
and high-risk groups had poor outcomes, and their BC was resistant to endocrine therapy. The latter group
demonstrated the highest rate of complete pathological response to neoadjuvant chemotherapy; the highest
activities in Myc, E2F1, Ras, b-catenin and IFN-g pathways; and poor prognosis predicted by 14 independent
prognostic signatures. On the basis of multivariate analysis, we found that this new gene signature, termed the
“ClinicoMolecular Triad Classification” (CMTC), predicted recurrence and treatment response better than all
pathological parameters and other prognostic signatures.
Conclusions: CMTC correlates well with current clinical classifications of BC and has the potential to be easily
integrated into routine clinical practice. Using FNABs, CMTC can be determined at the time of diagnostic needle
biopsies for tumors of all sizes. On the basis of using public databases as the validation cohort in our analyses,
CMTC appeared to enable accurate treatment guidance, could be made available in preoperative settings and was
applicable to all BC types independently of tumor size and receptor and nodal status. The unique oncogenic
signaling pathway pattern of each CMTC group may provide guidance in the development of new treatment
strategies. Further validation of CMTC requires prospective, randomized, controlled trials.
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T h ep r e s e n c eo fe s t r o g e nr e c e p t o r( E R ) ,p r o g e s t e r o n e
receptor (PR) and human epidermal growth factor
receptor 2 (Her2, also known as ERBB2)i sr o u t i n e l y
reported in the pathological assessment of breast cancer.
These three receptors have become the mainstay of clin-
ical and molecular classification of breast cancer [1,2].
In general, positive ER and PR status (ER+ and PR+,
respectively) are considered good prognostic indicators,
whereas positive Her2 status is considered a poor prog-
nostic indicator [2]. However, negative status in all three
receptors, that is, ER-, PR- and Her2-, also referred as
“triple-negative” (TN) status, is also considered a poor
prognostic indicator [3]. Because most basal-like subtype
tumors are TN, these terms have been used inter-
changeably, but in actual fact TN and basal-like breast
cancer are not the same and some of them can be dif-
ferentiated from each other by more in-depth molecular
characterization [3-5]. Oncologists generally divide
breast cancer into three clinically relevant groups when
making treatment decisions. Group 1 breast cancers are
generally low-risk and ER+ and respond well to endo-
crine therapy (ET), such as tamoxifen. Group 2 breast
cancers are ER+ but carry a poor prognosis despite ET,
and therefore chemotherapy is strongly recommended
for patients in this group. Group 3 breast cancers are
ER-, including Her2+ and TN cancers with a poor prog-
nosis that generally improves with chemotherapy, as
well as trastuzumab if necessary.
There is some indirect evidence that supports stratify-
ing Her2+ and TN breast cancer into the same high-risk
group. There is no significant difference in the clinical
outcomes of patients with the basal-like and Her2+ sub-
types of breast cancer [5-7]. Even though there is no
standard targeted systemic therapy for TN tumors
[3,4,8], such as trastuzumab for Her2+ tumors [9], the
rates of complete clinical response and complete patho-
logical response (pCR) to neoadjuvant chemotherapies
are also similar in both Her2+ and TN breast cancer
[10-12]. Recently, investigators in both the CALGB 9840
trial [13] and the NSABP-B31 trial [14,15] reported
responses of some Her2- breast cancers to trastuzumab
and raised some controversies about the classification of
breast cancer. Indirectly, these studies suggest that Her2
+ breast cancer may not be as different from TN breast
cancer as previously thought. Moreover, a relatively high
proportion of TN tumors have genomic profiles similar
to those of Her2+ tumors [16].
In the early 2000s, Perou and colleagues [6,7,17]
reported the intrinsic gene expression profile that
divides breast tumors into five or more molecular sub-
types. More recently, on the basis of oncogenic pathway
activity analysis, a more extensive classification with up
to 18 subtypes for breast cancer was reported [18]. It
remains a major challenge to use these molecular pro-
files to guide clinical treatment decisions [19] as they
become increasingly complex for patients and clinicians
alike and do not correlate with how breast cancer is
clinically classified. On the other hand, many prognostic
gene expression signatures that dichotomize selected
patient populations into good and poor prognosis
groups [20] lack the specificity to provide guidance on
various treatment options.
In this study, we aimed to develop a molecular test
that can be used preoperatively to guide treatment deci-
sions, such as whether to initiate neoadjuvant therapy.
For that reason, we decided to collect most of our clini-
cal specimens by fine-needle aspiration biopsy (FNAB)
taken from consecutive suspicious breast tumors at the
time of clinical diagnostic core biopsy. Our study
included relatively small breast cancers that had been
routinely excluded in previous studies in which fresh
surgical specimens or banked tissues were examined.
After confirming the clinical diagnoses and the presence
of tumor cells in the samples, gene profiles were gener-
ated from FNAB specimens by using a commercially
available genome-wide microarray platform. To keep the
molecular profiles clinically relevant, we asked whether
there is a molecular basis for the clinical practice of
lumping Her2+ and TN breast cancers together into the
same high-risk group. We analysed the molecular phe-
notype of Her2+/TN breast cancers and developed a
novel gene signature, termed the “ClinicoMolecular
Triad Classification” (CMTC), which divides all breast
cancers into three groups similar to the three risk
groups that oncologists refer to. Each CMTC group dis-
played a unique pattern of oncogenic signaling pathway
activities. To determine the clinical significance of the
CMTC classification scheme, we correlated the three
CMTC groups using standard pathology parameters,
and the results were reproduced in a large independent
validation cohort. Using multivariate analyses, CMTC
was the best among 14 published prognostic gene signa-
tures and clinical receptor statuses in predicting breast
cancer recurrence and treatment response.
Materials and methods
Patients and samples
The primary data set consisted of 161 prospectively
recruited, consecutive surgical patients with breast
tumors. A total of 172 tissue samples were collected at
the University Health Network (UHN) and Mount Sinai
Hospital (MSH), Toronto, ON, Canada. We excluded
samples from five benign tumors, five ductal carcinoma
in situ samples and two with a low RNA integrity num-
ber (RIN). That left 149 invasive breast cancers used as
the training cohort, including 121 FNABs, 10 core biop-
sies and 18 fresh frozen tissue specimens from the
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obtained by passing a 25-gauge needle into the tumor
10 to 20 times with suction using a 10-ml syringe. The
cells were suspended in CytoLyt solution (Cytyc Corp,
Marlborough, MA, USA) with an aliquot (10% vol/vol)
sent for cytological analysis by a cytopathologist (SB).
All FNAB samples had 80% or more malignant cells to
be included in this study. The remaining cells were cen-
trifuged and resuspended in 500 μl of RNA extraction
lysis buffer (Qiagen, Valencia, CA, USA), then snap-fro-
zen to -80°C for later processing. Core biopsies were
taken by our radiologist (SK) at the time of diagnostic
procedures. This study was approved by the Research
Ethics Boards at our institutions (UHN and MSH). All
patients were recruited prospectively and gave their
written informed consent to participate in the study.
The clinical follow-up data were collected until April
2010 with median follow-up of 31 months. The infor-
mation for the 149 patients is provided in Table S1 in
Additional file 1.
RNA extraction and microarray process
After we determined that the tissue samples satisfied
cytological criteria, the frozen FNAB lysates were
thawed and RNA was extracted using the RNeasy Micro
and RNeasy Mini kits (Qiagen) for FNABs and core
biopsies and UHN BioBank samples, respectively,
according to the manufacturer’s protocols. The quality
and quantity of the RNA were analyzed using an Agilent
2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA,
USA), and only the samples with a RIN higher than 5.5
were used in this study. The DNA microarray analyses
were then performed according to the Illumina Whole-
Genome Gene Expression direct hybridization assay pro-
tocols (Illumina Inc, San Diego, CA, USA) at The Cen-
tre of Applied Genomics (Toronto, ON, Canada).
Briefly, 250 ng of total RNA were reverse-transcribed
into cDNA, followed by in vitro transcription amplifica-
tion to generate biotin-labeled cRNA using the Ambion
TotalPrep RNA Amplification Kit (Applied Biosystems/
Ambion, Austin, TX, USA). Next, 750 ng of the labeled
cRNA were hybridized to Illumina HumanRef-8 v2
Expression BeadChips (Illumina Inc) overnight at 58°C.
After washing, signals were developed with streptavidin-
Cy3, and the BeadChips were scanned with the BeadAr-
ray Reader and processed using BeadStudio software
obtained from Illumina.
Microarray data sets and analyses
For the training cohort of 149 breast cancers, scanned
Illumina microarray image data were extracted and pro-
cessed by Gene Expression Module version 3.4 of Bead-
Studio software (Illumina Inc) using a background
subtraction and a quantile normalization method for
direct hybridization assays. Normalized hybridization
intensity values were adjusted by assigning a constant
value of 16 to any intensity value lower than 16, accord-
ing to the recommendation by the MAQC Consortium
[21]. A log2 expression ratio of an intensity value to the
average signal value for each transcript in all samples
was calculated. The training cohort microarray data are
available at the Gene Expression Omnibus website
[GSE:16987] [22].
An independent validation cohort consisting of pub-
licly available gene expression array data from 2,487
breast cancers was compiled from different published
original reference data sets that used Agilent and Affy-
metrix microarray platforms (Table S2 in Additional file
2). On the basis of the clinical treatment and the end
point, we used four subgroups of the validation cohort
to validate the CMTC classification derived from the
training cohort: (1) 2,239 cancers with follow-up
[23-36], (2) 1,058 cancers without adjuvant therapy
[24-31,34], (3) 756 ER+ cancers with or without ET
[24,26-29,33] and (4) 248 breast cancers treated with
neoadjuvant chemotherapy and pCR information [37].
The methods of platform-specific data treatment and
analyses are described in the Supplemental methods in
Additional file 3.
Results
Gene model and generation of the ClinicoMolecular Triad
Classification
Of the 149 evaluable breast cancers in the training
cohort (Table S1 in Additional file 1), we grouped all 26
Her2+ tumors and 18 TN tumors into one group and
the remaining 105 into another group in the first round
of supervised clustering analysis to identify the differen-
tially expressed genes. After two screens (see Supple-
mental methods in Additional file 3 and Figure S1 in
Additional file 4), we obtained a molecular profile of
Her2+/TN with 1,304 genes (1,349 oligonucleotide
probes; some genes were represented by multiple oligo-
nucleotide probes in the Illumina BeadChip. This mole-
cular profile appeared to divide the 149 tumors into a
familiar three-group pattern (Figure S1B in Additional
file 4) in which the third group included most of the
Her2+/TN tumors. Compared to the 16 published prog-
nostic gene expression signatures (Table S3 in Addi-
tional file 5), a total of 501 genes were found in the list
of the 1,304 genes matching 4% to 90.4% of the genes in
these prognostic signatures. These overlapped genes
included the following: (1) 29% (223 of 769) of the
genes in the estrogen-regulated gene expression signa-
ture [38] and 14% (10 of 70) of the Rotterdam signature
(76GS) [25]; (2) two ER-related gene signatures, 18% (92
of 512) of the intrinsic gene subtype signature (subtype)
[6,7] and 56% (28 of 50) of the modified subtype
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(PAM50) [23]; (3) 10% (106 of 1,025) of the embryonic
stem cell-like gene signature [39], 16% (29 of 181) of
the “invasiveness” gene signature [40], 20% (32 of 155)
of the stroma-derived prognostic predictor [41] and 14%
(8 of 58) of the CD44 signature [42]; four stem cell-
related gene signatures, 86% (93 of 108) of the Genomic
Grade Index (97GS) [26], 90% (75 of 83) of the prolif-
eration gene signature [31], 48% (11 of 23) of the TP53
mutation gene signature [29], 16% (73 of 462) of the
wound-response gene signature (WS) [43], 30% of the
lethal phenotype gene signature (37GS) [44]; and 42%
(26 of 62) of MammaPrint (70GS) [24] and 56% (9 of
16) of Oncotype DX [45], with these latter two being
the most widely used gene signatures [19].
To eliminate any potential confounding effects due to
these prognostic signatures, we excluded all of the 501
overlapping genes from the list of 1,304 genes and used
the remaining 803 genes (828 oligonucleotide probes)
(Table S4 in Additional file 6) to perform a clustering
analysis on the 149 tumors. The pattern with three
main clusters was again apparent in the dendrogram
(Figure 1A). The differential gene expression patterns
were significantly different among the three groups as
determined by performing an analysis of variance test (P
<0.00001 among the three groups) and a t-test (cor-
rected to P< 0.01 between any two groups). We termed
this 803-gene signature the “ClinicoMolecular Triad
Classification,” in which CMTC-3 contains most of the
Her2+/TN tumors (92.3%). This 803-gene set was used
as the new CMTC classifier for further analysis to cate-
gorize breast cancer in the validation cohort by a corre-
lation method (Supplemental methods in Additional file
3).
ClinicoMolecular Triad Classification correlates to clinical
parameters of breast cancer
To understand the relationship between the gene
expression profiles and the clinicopathological character-
istics of CMTC, the three CMTC tumor types were
compared based on their clinical and pathological para-
meters in 149 breast cancers in the training cohort and
in 2,487 breast cancers in the validation cohort (Table
1). The latter cohort consisted of all evaluable breast
cancers from published microarray data that had com-
plete pathological and clinical outcome data. We found
a statistically significant association between CMTC-3
tumors and larger size, high grade, low ER expression
and mostly Her2+/TN phenotypes in both training and
validation cohorts. In contrast, CMTC-1 tumors were
smaller and low-grade, had high ER expression and
were rarely the Her2+/TN phenotype. CMTC-2 tumors
were larger in size and high-grade, had high ER expres-
sion and were rarely the Her2+/TN phenotype.
ClinicoMolecular Triad Classification displays unique
patterns in oncogenic signaling pathways
To understand the biological processes underlying our
CMTC classification scheme, we compared the three
CMTC groups in 149 breast cancers in the training
cohort with 19 published microarray-based signaling
pathway signatures [18,46] (Figure 1B). We found the
highest activity in oncogenic signaling pathways invol-
v i n gH e r 2 ,M y c ,E 2 F 1 ,b-catenin and Ras in CMTC-3
and a negative correlation with the activities of ER, PR
and p53 wild-type pathways. In contrast, CMTC-1
tumors demonstrated low activity in Myc, E2F1, b-cate-
nin, Ras, IFN-g and Her2 signaling pathways and higher
activity in ER, PR and p53 wild-type pathways. CMTC-2
w a sd i s t i n c tf r o mt h eo t h e rt w og r o u p si nh a v i n gh i g h
activities in most of the oncogenic pathways that differ-
entiated CMTC-1 from CMTC-3, including the ER,
phosphatidylinositol 3-kinase (PI3K), Myc and b-catenin
pathways.
ClinicoMolecular Triad Classification unifies
prognostication from published prognostic gene
signatures
Of the 16 published prognostic gene signatures (Table
S3 in Additional file 5), 14 microarray-based signatures
were used as risk classifiers to evaluate the 149 breast
cancers in the training cohort. Even when all the over-
lapping genes from these published prognostic gene sig-
natures were excluded from the CMTC classifier gene
set, the tumors classified as carrying a “poor prognosis”
according to the published prognostic gene signatures
were mostly found in CMTC-3 and CMTC-2 and infre-
quently in CMTC-1 (Figure 1A). Comparison of the five
molecular subtypes [6,7] revealed that all the normal-
like tumors were found in CMTC-1, luminal A tumors
were distributed in both CMTC1 and CMTC-2, luminal
B tumors were mainly found in CMTC-2 and almost all
Her2+ and basal-like subtypes were found CMTC-3. A
similar distribution of the five molecular subtypes was
also observed when we used a newer intrinsic subtype
classifier, PAM50 [23], a 50-gene subtype predictor,
with more luminal B tumors grouped into CMTC-2
(Figure 1A).
ClinicoMolecular Triad Classification correlates with
clinical outcomes in breast cancer
During our first clinical follow-up (mean follow-up = 31
months) for the 149 cancers in the training cohort, five
recurrences (5 of 39 = 12.8%) were found in CMTC-3,
four (4 of 65 = 6.2%) were found in CMTC-2 and only
one (1 of 45 = 2.2%) was found in CMTC-1. However,
these results were not statistically significant, owing to a
low event rate in a short follow-up period (Figure 1A
and Table 1). In the validation breast cancer cohort with
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Figure 1 CMTC gene expression pattern, prognostic framework, and oncogenic pathway activity. (A) The 803-gene signature
(represented by 828 oligonucleotide probes) was used to classify the gene expression pattern in the 149 breast cancers in the training cohort
into the three main clusters of CMTC. Tumors in CMTC-3 were mostly Her2+/TN as well as CMTC-1 and CMTC-2 non-Her2+/TN. The bottom
multicolor bars indicating Her2+/TN are as follows: Her2+, deep pink; TN, dark blue. The multicolor bars indicating grade are as follows: grade 1,
dark blue; grade 2, dark orange; and grade 3, deep pink. The multicolor bars indicating subtype and PAM50 are as follows: normal-like, lime;
luminal A, blue; luminal B, dark orange; basal-like, dark blue; and Her2+, deep pink. CMTC = ClinicoMolecular Triad Classification; Her2 = human
epidermal growth factor receptor 2; TN = triple-negative; ER2+ = estrogen receptor-positive; TGFbRII = transforming growth factor b receptor
type II. (B) The probabilities of pathway activation of 19 published oncogenic pathway signatures in the 149 breast cancers in the training
cohort. Blue indicates low pathway activity, and red indicates high activity. EGFR = epidermal growth factor receptor; PAM50 = 50-gene
prediction analysis of microarray; PI3K = phosphatidylinositol 3-kinase; PR = progesterone receptor; STAT3 = signal transducer and activator of
transcription 3.
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rate was observed: 40.5% in CMTC-2 and 39% in
CMTC-3 compared to 18.6% in CMTC-1 (Table 1). The
Kaplan-Meier analyses for relapse-free survival showed
significant differences between CMTC-1 and CMTC-2
and also between CMTC-1 and CMTC-3 breast cancer
patients in 2,239 breast cancers overall (Figure 2A) and
in 1,058 breast cancers in which the patients in the vali-
dation cohort did not receive any adjuvant therapy (Fig-
ure 2B). CMTC-2 and CMTC-3 patients had similar
poor prognoses (Figure 2A and 2B). By using a Cox pro-
portional hazards model (Table S5 in Additional file 7),
we compared CMTC-2 and CMTC-3 to CMTC-1 and
found that, on the basis of univariate analysis, the
hazard ratio (HR) was the highest among all clinico-
pathological parameters and prognostic signatures (HR
= 2.40, 95% confidence interval (95% CI) = 1.88 to 3.05;
P< 0.01). By using multivariate analysis, we again found
that CMTC had the highest HR (HR = 1.73, 95% CI =
1.23 to 2.44; P< 0.01) among all clinicopathological
p a r a m e t e r s( a g e ,n o d a ls t a t u s ,t u m o rs i z e ,t u m o rg r a d e
and receptor status). Among all the prognostic gene sig-
natures, the HR of CMTC was the highest in univariate
analysis (HR = 2.40, 95% CI = 1.88 to 3.05; P< 0.0001)
and the second highest in multivariate analysis (HR =
1.43, 95% CI = 1.00 to 2.04; P< 0.05). Prediction of
recurrence using CMTC was also better than that using
receptor status Her2+/TN (Her2+/TN vs non-Her2
+/TN) (Figures 2C and 2D). Her2+/TN receptor status
had a HR of 1.56 in univariate analysis (95% CI = 1.27
to 1.91; P< 0.01) and 1.35 in multivariate analysis (95%
CI = 0.91 to 2.00; P =0 . 1 3 ) ,s u g g e s t i n gt h a tC M T Cw a s
more robust than receptor status alone in predicting
survival. Hence, CMTC is an independent, strong pre-
dictor of recurrence in breast cancer.
ClinicoMolecular Triad Classification correlates with the
benefits of endocrine therapy
In the validation cohort, from among the group of 756
patients with ER+ breast cancer, 405 received ET (390
patients received tamoxifen and 15 patients received an
unspecified hormonal therapy) and the remaining 351
did not receive any adjuvant therapy. These two groups
were not matched, as they were not derived from a ran-
domized, controlled trial. To identify the association
between CMTC and tumor response to ET, we com-
pared the relapse-free survival rates between the two
groups. Interestingly, we did not see any benefit of ET
(P = 0.7735) when we compared the treated and
untreated groups in the entire 756 ER+ breast cancer
population (Figure 3A). However, when we divided the
756 ER+ patients into the three CMTC groups, patients
Table 1 Clinical and pathological variables in ClinicoMolecular Triad Classification of breast cancer in training and
validation cohorts
Training cohort (n = 149) Validation cohort (n = 2,487)
Variables CMTC-1, n (%) CMTC-2, n (%) CMTC-3, n (%) P value CMTC-1, n (%) CMTC-2, n (%) CMTC-3, n (%) P value
Total 45 (30.2) 65 (43.6) 39 (26.2) 803 (32.3) 794 (31.9) 890 (35.8)
Age
< 50 15 (33.3) 18 (27.7) 17 (43.6) 2.51E-01 231 (39.1) 202 (34.9) 299 (43.6) 6.30E-03
≥ 50 30 (66.7) 47 (72.3) 22 (56.4) 360 (60.9) 377 (65.1) 386 (56.4)
Size
≤ 2 cm 23 (51.1) 21 (32.3) 11 (28.2) 5.62E-02 361 (54.7) 209 (32.5) 235 (32.4) 1.05E-20
> 2 cm 22 (48.9) 44 (67.7) 28 (71.8) 299 (45.3) 434 (67.5) 490 (67.6)
LN- 26 (59.1) 21 (32.3) 24 (61.5) 3.27E-03 490 (66.8) 436 (59.2) 498 (60.3) 4.37E-03
LN+ 18 (40.9) 44 (67.7) 15 (38.5) 243 (33.2) 301 (40.8) 328 (39.7)
Grade
1 13 (28.9) 1 (1.5) 0 (0.0) 5.55E-13 270 (39.4) 81 (12.2) 29 (3.9) 3.47E-130
2 27 (60.0) 30 (46.2) 6 (15.4) 342 (49.9) 339 (51.2) 220 (29.6)
3 5 (11.1) 34 (52.3) 33 (84.6) 74 (10.8) 242 (36.6) 495 (66.5)
ER- 0 (0.0) 1 (1.5) 35 (89.7) 1.16E-27 69 (8.6) 45 (5.7) 584 (65.6) 2.60E-211
ER+ 45 (100) 64 (98.5) 4 (10.3) 734 (91.4) 749 (94.3) 306 (34.4)
Her2+/TN
No 42 (93.3) 60 (92.3) 3 (7.7) 1.87E-22 715 (89.0) 668 (84.1) 238 (26.7) 1.45E-197
Yes 3 (6.7) 5 (7.7) 36 (92.3) 88 (11.0) 126 (15.9) 652 (73.3)
Recurrence
No 44 (97.8) 61 (93.8) 34 (87.2) 1.49E-01 595 (81.4) 423 (59.5) 486 (61.0) 1.99E-22
Yes 1 (2.2) 4 (6.2) 5 (12.8) 136 (18.6) 288 (40.5) 311 (39.0)
CMTC = ClinicoMolecular Triad Classification; LN = lymph node status; ER = estrogen receptor; TN = triple-negative.
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eral (Figure 3B), particularly in the 115 patients treated
with ET compared to the 184 untreated patients (Figure
3C). In fact, the benefit of ET was observed only in the
CMTC-1 patients (Figure 3C) and not in the CMTC-2
and CMTC-3 patients (Figure 3D). Hence, in our valida-
tion cohort, CMTC appeared to predict a benefit from
ET in ER+ breast cancer. The other gene signatures
could demonstrate only varying degrees of prognostic
significance, but did not predict the benefit of ET in the
756 ER+ breast cancer patients (Table S6 in Additional
file 8). When we tried to stratify the patients into differ-
ent cancer stages, only a limited number of cases in the
validation cohort had complete staging information. On
the basis of all the data available, we observed only a
trend toward better relapse-free survival associated with
ET in treated versus untreated ER+, CMTC-1 patients
at stage I (n =1 5 5 ;P = 0.0967) and at stage II or worse
(n = 142; P = 0.0612) (Figure S2 in Additional file 9).
ClinicoMolecular Triad Classification predicts complete
pathological response to neoadjuvant chemotherapy
To determine whether CMTC could predict tumor
responses to neoadjuvant chemotherapy, 248 breast can-
cer patients [37] from the validation cohort who
received neoadjuvant chemotherapy were studied to
determine the relationship between CMTC groups and
complete pCR. The highest pCR rate was found in
CMTC-3 breast cancer (42%), with much lower pCR
rates in CMTC-1 breast cancer (6%) and CMTC-2
breast cancer (8%). Her2+/TN breast cancer patients
had a 37% pCR rate (Figure 4A). To compare the rela-
tive ability of receptor status (Figure 4B) and gene signa-
ture (Table S7 in Additional file 10) to predict pCR, we
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C1 vs.C2: HR=2.60(1.99-3.39), P=3.90E-13
C1 vs.C3: HR=2.27(1.74-2.96), P=5.90E-10
0 5 10 15 20
0
20
40
60
80
100
CMTC-1 (n=378)
CMTM-2 (n=316)
CMTM-3 (n=364)
Relapse-free survival (years)
P
e
r
c
e
n
t
 
s
u
r
v
i
v
a
l
Overall breast cancers, n=2239
HR=1.56(1.35-1.81), P=2.28E-09
0 5 10 15 20
0
20
40
60
80
100
Non-Her2+/TN (n=1484)
Her2+/TN (n=755)
Relapse-free survival (years)
P
e
r
c
e
n
t
 
s
u
r
v
i
v
a
l
No-adjuvant-treated cancers, n=1058
HR=1.56(1.27-1.91), P=1.91E-05
0 5 10 15 20
0
20
40
60
80
100
Non-Her2+/TN (n=710)
Her2+/TN (n=348)
Relapse-free survival (years)
P
e
r
c
e
n
t
 
s
u
r
v
i
v
a
l
Overall breast cancers, n=2239
C1 vs.C2: HR=2.71(2.21-3.33), P=2.18E-23
C1 vs.C3: HR=2.63(2.15-3.22), P=1.77E-22
0 5 10 15 20
0
20
40
60
80
100
CMTC-1 (n=731)
CMTC-2 (n=711)
CMTC-3 (n=797)
Relapse-free survival (years)
P
e
r
c
e
n
t
 
s
u
r
v
i
v
a
l
A B
C D
Figure 2 CMTC and Her2+/TN status in prediction of the clinical outcomes. Kaplan-Meier analysis was used to compare relapse-free patient
survival among the CMTC-1 (C1), CMTC-2 (C2) and CMTC-3 (C3) in (A) 2,239 breast cancers overall and (B) 1,058 nonadjuvant treatment cancers,
as well as in (C) Her2+/TN and non-Her2+/TN 2,239 breast cancers overall and (D) 1,058 nonadjuvant treatment cancers. The hazard ratios with
95% confidence intervals in parentheses were calculated using the Cox proportional hazards method. The P values were determined using the
log-rank test. CMTC = ClinicoMolecular Triad Classification; Her2 = human epidermal growth factor receptor 2; HR = hazard ratio; TN = triple-
negative.
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Page 7 of 14calculated the area under the curve (AUC) using recei-
ver operating characteristic (ROC) curve analyses. We
found that CMTC-3 tumors had the highest AUC value
(0.754) compared to Her2+/TN tumors (0.733), Her2+
tumors (0.604) and TN tumors (0.629) (Figure 4B). In
addition, tumors with a high positive correlation with
CMTC-3 were significantly correlated with pCR in 111
Her2+/TN tumors (Figure 4C) and in all 248 che-
motherapy-treated tumors (Figure 4D). When we com-
pared CMTC to 14 published prognostic gene
signatures, the highest AUC values were found in the
CMTC-3 group in all 248 cancers (0.811) (95% CI =
0.76 to 0.86; P< 0.001) and in 111 Her2+/TN tumors
(0.718) (95% CI = 0.63 to 0.80; P< 0.001). CMTC was
also better than the five intrinsic subtypes and PAM50,
as well as the other gene signatures, in predicting pCR
(Table S7 in Additional file 10). For comparison pur-
poses, we also tabulated the sensitivity, specificity, posi-
tive predictive value (PPV), negative predictive value
(NPV) and accuracy of CMTC in predicting pCR
together with the other gene signatures (Table S8 in
Additional file 11). Again, CMTC remained one of the
best predictors among these gene signatures, with a
good balance between sensitivity and specificity.
Discussion
Using the gene signature generated from the training
cohort, we identified an expression pattern of 1,304
genes that divided the 149 breast cancers into three dis-
tinct groups, in which Her2+/TN breast cancer repre-
sented 90.4% of the 39 group 3 tumors (Figure S1B in
Additional file 4). Of the 1,304 genes, a total of 501
genes overlapped with 16 published prognostic gene sig-
natures (Table S3 in Additional file 5), matching 4% to
90.4% of the genes in these gene signatures. The high
rate of the overlapped genes across the different pub-
lished gene signatures suggests strong clinical and biolo-
gical relevance.
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Figure 3 CMTC and the prediction of benefits of ET in ER+ breast cancer. Kaplan-Meier analysis was used to compare patients’ relapse-free
survival (A) between ET treatment and no treatment (B) among all 756 ER+ breast cancers, (C) between the three CMTC groups of all 756 ER+
breast cancers and ET treatment vs no treatment in 299 CMTC-1-only ER+ cancers and (D) and ET treatment vs no treatment between 457
CMTC-2- and CMTC-3-only ER+ cancers. The P values were determined using the log-rank test. CMTC = ClinicoMolecular Triad Classification; ER =
estrogen receptor; ET = endocrine therapy; TN = triple-negative.
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Page 8 of 14To remove any potential confounding effects of the
overlapping genes from these published gene signatures,
we excluded all of the 501 genes in these published
gene signatures that overlapped with our original 1,304-
gene set. As a result, a unique 803-gene set (represented
by 828 oligonucleotide probes in the Illumina BeadChip
assay) was derived. Using the new probe set, we
observed a dendrogram with three main clusters which
we have termed the “ClinicoMolecular Triad Classifica-
tion.” In the CMTC, the gene expression pattern of
CMTC-1 is completely opposite that of CMTC-3 and
results in a distinct, intermediate CMTC-2 (Figure 1A).
The tumors in CMTC-1 and CMTC-2 were mostly ER+
and rarely Her2+/TN. However, of the 44 Her2+/TN
tumors, 36 (81.82%) were found in CMTC-3. When we
applied the CMTC to 866 Her2+/TN tumors in the
2,487 validation breast cancers, 652 (75.3%) were
assigned to the CMTC-3 group (Table 1). Furthermore,
the prognostic predictability of CMTC agreed very well
with all 14 prognostic gene signatures that were devel-
oped independently using different commercial microar-
ray platforms (Table S3 in Additional file 5). Using
these prognostic gene signatures, we found tumors car-
rying a poor prognosis (from signatures dichotomized
into good vs poor prognosis) mostly in the CMTC-2
and CMTC-3 cohorts (Figure 1A). There was also a
close correlation between the five molecular subtypes
[6,7,23].
In both training and validation cohorts, the tumors in
CMTC-1 were of smaller size and lower grade than
tumors in the CMTC-2 and CMTC-3 groups. In the
validation cohort, patients in the CMTC-1 cohort were
found to have significantly better clinical outcomes than
the patients in the CMTC-2 and CMTC-3 groups as
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Figure 4 CMTC and prediction in pCR of neoadjuvant chemotherapy. (A) The percentage of pCR between non-Her2+/TN tumors (non-H
+/TN) and Her2+/TN tumors (H+/TN) and within the three CMTC groups of the 248 breast cancers with neoadjuvant chemotherapy. (B)
Comparison of area under the curve (AUC) to predict pCR in CMTC-3 tumors (CMTC-3 vs CMTC-1 and CMTC-2; P = 0.0001), Her2+/TN tumors
(Her2+/TN vs non-Her2+/TN; P = 0.0001), Her2+ tumors (Her2+ vs Her2-; P = 0.0245) and TN tumors (TN vs non-TN; P = 0.0052). By comparing
the gene profiles of individual tumors with CMTC-3, a correlation coefficient (r) was calculated as an index reflecting its degree of similarity to
the expression pattern of CMTC-3 tumors. The two graphs show the relationship between r value and pCR (C) in the 111 Her2+/TN cancers and
(D) in all 248 cancers. pCR status (deep pink), Her2+ status (deep pink) and TN status (dark blue), respectively, are indicated by the bottom bars.
AUC = area under the curve; CMTC = ClinicoMolecular Triad Classification; Her2 = human epidermal growth factor receptor 2; pCR =
pathological response; TN = triple-negative.
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Page 9 of 14demonstrated in 2,239 breast cancers overall (Figure
2A), 1,058 non-adjuvant-treated cancers (Figure 2B) and
756 ER+ cancers (Figure 3B). CMTC was better at pre-
dicting clinical outcomes than receptor status alone
(Figure 2C and 2D), suggesting that it reflects not only
the presence of the receptors but also pathway activity.
Furthermore, on the basis of the survival data of 1,058
breast cancer patients from the validation cohort who
did not receive adjuvant therapy, CMTC prognosticated
clinical outcomes significantly better than other pub-
lished gene signature predictors (Table S5 in Additional
file 7).
Another potential application of our molecular classi-
fication is in the prediction of response to adjuvant ET
and neoadjuvant chemotherapy. Because of the limita-
tion of using public microarray databases as our valida-
tion cohort, we are not able to conclude that CMTC
can predict treatment response [47,48]. We were not
able to match the treatment arms according to CMTC
groups, as they were not randomized as such. Therefore,
our intent in this study was to demonstrate an associa-
tion between CMTC and tumor response to a specific
treatment modality by treating each breast cancer case
in our validation cohort as a randomly selected patient.
CMTC-1 patients appeared to benefit the most from ET
in terms of recurrence-free survival compared to
patients with ER+ breast cancer who did not receive ET
(Figure 3C), but the benefits of ET were not significant
in CMTC-2 and CMTC-3 patients (Figure 3D). Using
t h es a m ev a l i d a t i o nc o h o r t ,w ef o u n dt h a tC M T Ca l s o
appeared to be better than other published prognostic
gene signatures in predicting responses to ET (Table S6
in Additional file 8). Figure 3A shows that the benefit of
ET was nullified by the fact that most of the ET-treated
breast cancers were classified as CMTC-2 and CMTC-3
(n = 290) (Figure 3D) rather than CMTC-1 (n =1 1 5 )
(Figure 3C). Conversely, most of the group that received
no treatment were classified as CMTC-1. Furthermore,
it may be possible that ET-treated patients presented at
a later stage of their disease than did those who received
no treatment, given that the breast cancers classified as
CMTC-2 and CMTC-3 were associated with larger
tumor size (see preceding paragraph). However, sub-
group analyses failed to reach statistical significance, as
many cases in the validation cohort lacked complete sta-
ging information. On the basis of all the data available,
we did detect a trend toward better relapse-free survival
in both stage I (n =1 5 5 ;P = 0.0967) and stage II or
worse (n = 142; P = 0.0612) CMTC-1 ER+ ET-treated
patients (Figure S2 in Additional file 9). Therefore, in
our validation cohort, there was more ET given to so-
called “nonresponders” than to “responders.” This brings
up an important point: If we do not have a better way
to classify ER+ breast cancer and use ET to treat all ER
+ breast cancers equally, we may not achieve the desired
clinical benefit. This result will need to be confirmed in
a randomized, controlled trial with a larger set of ER+
patients and complete staging information.
With regard to response to neoadjuvant chemother-
apy, CMTC-3 tumors demonstrated a higher rate of
complete pCR to neoadjuvant chemotherapy than the
other two CMTC groups did (Figure 4A). The ability of
CMTC to predict pCR after neoadjuvant chemotherapy
is not only superior to receptor status (Her2+, TN and
Her2+/TN) (Figure 4B) but also better than the other
i n d e p e n d e n tp r o g n o s t i cg e n es i g n a t u r e s( T a b l eS 7i n
Additional file 10). Several gene signatures have been
reported to predict pCR or clinical response to specific
types of chemotherapy in relatively few, highly selected
patients (see Table 1 in [49]). Interestingly, the NPV,
PPV and accuracy of these chemotherapy-specific pre-
dictors are all within a range similar to that of CMTC,
except that CMTC is applicable to different chemother-
apeutic regimens in all breast cancers and is prognostic
in addition to its predictive power for pCR.
To examine the biological processes that may be
involved in CMTC, oncogenic signaling pathway ana-
lyses were performed in the training cohort, which
showed that CMTC-3 tumors had the highest activity in
Her2 and other oncogenic signaling pathways (Myc,
E2F1, b-catenin, Ras and IFN-g) and the lowest activity
in ER, PR and wild-type p53 pathways (Figure 1B). This
oncogenic pathway pattern was completely opposite to
that of CMTC-1 tumors. CMTC-2 was distinct from the
other two groups in having high activity in most of the
oncogenic pathways that differentiated CMTC-1 from
CMTC-3. Unlike CMTC-1 and CMTC-3 tumors,
CMTC-2 tumors did not respond well to the two com-
mon treatment strategies, namely, ET and chemother-
apy. To find new molecular targets for CMTC-2 tumors,
our next study will focus on the molecular profiles of
CMTC-2 tumors to identify novel treatment strategies.
For example, most CMTC-2 tumors displayed activity in
the PI3K and b-catenin pathways, and patients with
these tumors may benefit from targeted therapies that
disrupt these pathways and ER blockage.
The microarray data of our training cohort were gen-
erated predominantly from FNABs taken from an unse-
lected cohort of clinical patients prior to any surgical or
medical interventions. Thus, CMTC could be used to
help in making treatment decisions at the point of diag-
nosis. Since CMTC can predict treatment outcomes bet-
ter than standard surgical pathological parameters,
FNABs taken for CMTC group assignment of breast
cancer patients in the future may help clinicians decide
which patients will benefit from neoadjuvant che-
motherapy. Another advantage of using FNABs in our
study was the ability to include smaller tumors, which
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Page 10 of 14are becoming more common in the era of screening
mammography but are routinely excluded from tissue
banking because of size limitations, an issue shared by
most reported microarray-based prognostic gene signa-
tures. FNABs appeared to collect malignant epithelial
cells selectively, as demonstrated by over 80% of malig-
nant cells found in our FNAB specimens. Our microar-
r a yd a t aw e r ea l s ov e r yr e p r o d u c i b l ei nd u p l i c a t e
specimens (R = 0.9918) (Supplemental methods in Addi-
tional file 3).
The gene profiles used to develop CMTC were
derived from a commercially available whole-genome
microarray platform that has become more affordable
than currently available multigene assays, such as Mam-
maPrint (70GS; Agendia Inc, Irvine, CA, USA) and
Oncotype DX (Genomic Health, Redwood City, CA,
USA), which report only a limited number of genes
[24,45] at a high cost [19,50]. Furthermore, the clinical
application of CMTC may be extended to other com-
mercial genome-wide microarray platforms, as we have
demonstrated the reproducibility of CMTC classification
in the validation cohort derived independently from dif-
ferent DNA microarray platforms. Another potential
application of using a whole-genome microarray plat-
form is the ability to perform pathway activity analyses
to provide insights into the biological processes operat-
ing within the breast cancer, and this may help to iden-
tify novel treatment strategies.
During the past decade, the focus of research has been
on finding a gene signature that is both prognostic and
predictive with high accuracy while containing only a
small number of genes. However, with better microarray
technology available at a lower price, we are able to gen-
e r a t em i c r o a r r a yd a t at h a ti sh i g h l yr e p r o d u c i b l ea n d
cheaper than any of the commercially available gene sig-
natures. It is well known that single-gene estimation (for
example, ER) of individual pathway activity is not accu-
rate enough to predict treatment outcomes (for exam-
ple, response to ET). Therefore, we believe that by using
a larger number of genes, the test will be less susceptible
to variations caused by errors in measuring individual
genes and thus will result in a more reliable determina-
tion of the activity levels of critical oncogenic pathways
involved in prognosis and treatment response. With the
current vastly improved computing power and storage
c a p a c i t y ,w ea d v o c a t eu s i n gg e n o m e - w i d eg e n ep r o f i l e s
to provide a more comprehensive genomic analysis
comprising a portfolio of current gene expression pro-
files that includes CMTC, complete oncogenic pathway
analyses and the potential for future analyses if pathway
gene signatures are further refined.
Finally, CMTC will need to be validated by prospec-
tive, randomized, clinical studies, which are in our
future plans. On the basis of our present study, we can
say that CMTC has the potential to guide treatment
decisions at the time of diagnosis, such as the considera-
tion of treating CMTC-3 breast cancer with neoadjuvant
chemotherapy, CMTC-1 with ET alone and CMTC-2
with a combination of ET and chemotherapy in adjuvant
settings. We note that CMTC-2 remains a challenge in
terms of finding an effective treatment. Additional tar-
geted therapies are necessary, and our oncogenic path-
w a ya n a l y s e sm a yp r o v i d es o m eg u i d a n c ei nf i n d i n g
targets for CMTC-2.
Conclusions
On the basis of the Her2+/TN molecular phenotype, we
developed an 803-gene signature, the ClinicoMolecular
Triad Classification system, which is a new, clinically
useful molecular classification scheme for breast cancer.
Similarly to current clinical practice, CMTC divides
breast cancer into three distinct groups. Patients
assigned to CMTC-1 have a better prognosis and signifi-
cantly benefit from ET. Patients in categories CMTC-2
and CMTC-3 have worse clinical outcomes than
CMTC-1 patients, with CMTC-3 tumors tending to dis-
p l a yah i g h e rr a t eo fc o m p l e t ep C Ri nr e s p o n s et o
neoadjuvant chemotherapies. On the basis of our valida-
tion analyses using all evaluable public microarray data,
the benefits of our clinicomolecular grouping include (1)
the capacity to determine the patient’sC M T Cg r o u p
preoperatively, which is especially important in neoadju-
vant settings; (2) a further improvement in the ability to
predict clinical outcomes and treatment responses to ET
and neoadjuvant chemotherapy over clinical receptor
status and currently available gene signatures; (3) a
molecular classification system that is more generaliz-
able than other prognostic gene signatures (including
ER+, ER-, tumors of any size, node-positive or node-
negative breast cancer) and was reproducible in the vali-
dation cohort, from which the data were generated
using different commercially available microarray plat-
forms; and (4) the potential to identify novel molecular
targets for each CMTC breast cancer group, especially
for CMTC-2 tumors that do not respond well to either
ET or chemotherapy. Once we have validated the
CMTC system in prospective clinical trials, we plan to
introduce it into the clinic to help physicians guide
treatment decision-making.
Additional material
Additional file 1: Supplementary Table S1 Summary of patient
information and tumor pathological data for the training cohort of
149 breast cancers. CMTC = ClinicoMolecular Triad Classification; EIC =
extensive intraductal component; IDC = invasive ductal carcinoma; LVI =
lymphovascular invasion; PTID = Patient’s identity number; RIN = RNA
integrity number.
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Page 11 of 14Additional file 2: Supplementary Table S2 Summary of resource,
platform, adjuvant treatment status and clinical end point of the
microarray data sets used in this study. DMFS = distant metastasis-
free survival; RFS = relapse-free survival.
Additional file 3: Supplementary methods. File containing
descriptions of microarray data resources, platform-specific data
treatment and analyses, integration of published gene expression
signatures and signaling pathway signatures, and generation of gene
expression profiles for the Her2+/TN phenotype. ANOVA = analysis of
variance; ER = estrogen receptor; ESR1 = estrogen receptor 1 gene; GEO
= Gene Expression Omnibus; Her2 = human epidermal growth factor
receptor 2; MAQC = MicroArray Quality Control project; PAM50 = 50-
gene prediction analysis of microarray; PM-MM = Pairs of Perfect Match
(PM) and Mismatch(MM) oligonucleotide probes; PR = progesterone
receptor; TN = triple-negative; WS = wound-response gene signature.
Additional file 4: Supplementary Figure S1 Generation of gene
expression profile for Her2+/TN phenotype in the training cohort (n
= 149). (A) First screening of Her2+/TN-related genes. A group of 44
Her2+/TN breast cancers were used to distinguish the gene expression
from the other 105 tumors. A total of 1,428 probes were selected at a
level of the Bonferroni-corrected P value < 0.01. By using the 1,428-probe
set in a hierarchical clustering pattern, 39 tumors that were mostly Her2
+/TN formed group 3, with two other subgroups emerging on the heat
map: groups 1 and 2. (B) Second screening for the most differentially
expressed genes between the three groups. By performing an analysis of
variance test, 1,349 probes were selected at a level of P < 0.001 among
the three groups. A three-cluster pattern is apparent on the heat map,
based on hierarchical clustering analysis using the 1,349-probe set. The
tumors with Her2+/TN status were 2.4% (1 of 42) in group 1, 10.3% (7 of
68) in group 2 and 92.3% (36 of 39) in group 3. The bottom color bars
represent Her2+ (deep pink) and TN (blue). ANOVA = analysis of
variance; Her2 = human epidermal growth factor receptor 2; TN = triple-
negative.
Additional file 5: Supplementary Table S3 Summary of name,
definition, platform and reference of the prognostic signatures
used in this study and the overlapped genes between
ClinicoMolecular Triad Classification and published independent
breast cancer gene expression prognostic signatures. TGF =
transforming growth factor.
Additional file 6: Supplementary Table S4 CMTC 828-probe set
including Illumina probe ID, gene symbol and expression log2 ratio
for each of the 828 probes, as well as the mean log2 ratios and
statistical relationships among the three CMTC groups of 149
breast cancers in the training cohort. CMTC = ClinicoMolecular Triad
Classification.
Additional file 7: Supplementary Table S5 Univariate and
multivariate analyses of standard clinicopathological parameters, 14
independent gene signatures and CMTC as prognostic indicators
for relapse among 1,058 breast cancer patients without adjuvant
therapy in the validation cohort. CI = confidence interval; CMTC =
ClinicoMolecular Triad Classification; ER = estrogen receptor; ERGS =
estrogen-regulated gene expression signature; ESGS = embryonic stem
cell-like gene signature; Her2 = human epidermal growth factor receptor
2; IGS = “invasiveness” gene signature; LN = lymph node status; PAM50
= 50-gene prediction analysis of microarray; SDPP = stroma-derived
prognostic predictor; TGFbRII = transforming growth factor b receptor
type II; TN = triple-negative; WS = wound-response gene signature.
Additional file 8: Supplementary Table S6 Association between
relapse-free survivals and Her2+/TN status. Fourteen gene signatures
and CMTC in the seven hundred fifty-six ER+ breast cancer patients with
or without ET. ER = estrogen receptor; ERGS = estrogen-regulated gene
expression signature; ESGS = embryonic stem cell-like gene signature;
PAM50 = 50-gene prediction analysis of microarray; SDPP = stroma-
derived prognostic predictor; TGFbRII = transforming growth factor b
receptor type II; TN = triple-negative; WS = wound-response gene
signature.
Additional file 9: Supplementary Figure S2 Benefits of ET in CMTC-1
ER+ breast cancer at different cancer stages. Kaplan-Meier analyses
were used to compare relapse-free survival between ET-treated and no-
treatment ER+ breast cancer (A) in 155 stage I CMTC-1 cancers and (B)
in 142 stage II or worse (stage II+) CMTC-1 cancers. The P values were
determined by using the log-rank test. CMTC = ClinicoMolecular Triad
Classification; ER = estrogen receptor; ET = endocrine therapy.
Additional file 10: Supplementary Table S7 Receiver operating
characteristic analysis of the ability of independent gene
expression signatures to predict pathological complete responses
in breast cancer treated with neoadjuvant chemotherapy.C I=
confidence interval; CMTC = ClinicoMolecular Triad Classification; ERGS =
estrogen-regulated gene expression signature; ESGS = embryonic stem
cell-like gene signature; Her2 = human epidermal growth factor receptor
2; IGS = “invasiveness” gene signature; LumA = luminal A; LumB =
luminal B; PAM50 = 50-gene prediction analysis of microarray; SDPP =
stroma-derived prognostic predictor; TGFbRII = transforming growth
factor b receptor type II; TN = triple-negative; WS = wound-response
gene signature.
Additional file 11: Supplemental Table S8 The prediction of pCRs in
248 breast cancer patients treated with neoadjuvant chemotherapy
on the basis of CMTC and 14 independent prognostic gene
expression signatures. CMTC = ClinicoMolecular Triad Classification;
PAM50 = 50-gene prediction analysis of microarray; SDPP = stroma-
derived prognostic predictor; TGFbRII = transforming growth factor b
receptor type II; WS = wound-response gene signature.
Abbreviations
AUC: area under the curve; CMTC: ClinicoMolecular Triad Classification; ER:
estrogen receptor; ET: endocrine therapy; FNAB: fine-needle aspiration
biopsy; Her2: human epidermal growth factor receptor 2 (also known as
ERBB2); IFN: interferon; NPV: negative predictive value; pCR: pathological
response; PI3K: phosphatidylinositol 3-knase; PPV: positive predictive value;
PR: progesterone receptor; RIN: RNA integrity number; ROC: receiver
operating characteristic analysis; RT-PCR: reverse transcriptase polymerase
chain reaction; TN: triple-negative (ER-/PR-/Her2-).
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